Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hypophosphataemia is common in patients with aneurysmal subarachnoid haemorrhage

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Robert A Hegele
  • Jan Borén
  • Henry N Ginsberg
  • Marcello Arca
  • Maurizio Averna
  • Christoph J Binder
  • Laura Calabresi
  • M John Chapman
  • Marina Cuchel
  • Arnold von Eckardstein
  • Ruth Frikke-Schmidt
  • Daniel Gaudet
  • G Kees Hovingh
  • Florian Kronenberg
  • Dieter Lütjohann
  • Klaus G Parhofer
  • Frederick J Raal
  • Kausik K Ray
  • Alan T Remaley
  • Jane K Stock
  • Erik S Stroes
  • Lale Tokgözoğlu
  • Alberico L Catapano
Vis graf over relationer

Genome sequencing and gene-based therapies appear poised to advance the management of rare lipoprotein disorders and associated dyslipidaemias. However, in practice, underdiagnosis and undertreatment of these disorders are common, in large part due to interindividual variability in the genetic causes and phenotypic presentation of these conditions. To address these challenges, the European Atherosclerosis Society formed a task force to provide practical clinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. The task force also recognises the scarcity of quality information regarding the prevalence and outcomes of these conditions. Collaborative registries are needed to improve health policy for the care of patients with rare dyslipidaemias.

OriginalsprogEngelsk
TidsskriftThe Lancet Diabetes and Endocrinology
Vol/bind8
Udgave nummer1
Sider (fra-til)50-67
Antal sider18
ISSN2213-8587
DOI
StatusUdgivet - jan. 2020

Bibliografisk note

Copyright © 2020 Elsevier Ltd. All rights reserved.

ID: 59943136